Wall Street analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX) will post earnings per share of ($0.28) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.33) to ($0.25). Agile Therapeutics reported earnings of ($0.29) per share in the same quarter last year, which would suggest a positive year over year growth rate of 3.4%. The company is expected to report its next quarterly earnings report on Monday, August 14th.

According to Zacks, analysts expect that Agile Therapeutics will report full-year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.22) to ($1.03). For the next fiscal year, analysts expect that the firm will post earnings of ($0.60) per share, with EPS estimates ranging from ($1.21) to ($0.21). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Agile Therapeutics.

AGRX has been the topic of several analyst reports. FBR & Co set a $10.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 11th. Cantor Fitzgerald lifted their price target on shares of Agile Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, April 4th. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Monday, March 13th. Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 13th. Finally, ValuEngine lowered shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.92.

In other news, insider Renee Selman purchased 53,333 shares of the business’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of $3.68 per share, with a total value of $196,265.44. Following the completion of the acquisition, the insider now owns 53,333 shares of the company’s stock, valued at $196,265.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was purchased at an average cost of $3.51 per share, for a total transaction of $35,100.00. Following the completion of the acquisition, the chairman now directly owns 151,587 shares of the company’s stock, valued at approximately $532,070.37. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in AGRX. Renaissance Technologies LLC raised its position in Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 43,300 shares in the last quarter. Geode Capital Management LLC raised its position in Agile Therapeutics by 72.0% in the first quarter. Geode Capital Management LLC now owns 201,152 shares of the specialty pharmaceutical company’s stock valued at $644,000 after buying an additional 84,212 shares in the last quarter. State Street Corp raised its position in Agile Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 142,442 shares of the specialty pharmaceutical company’s stock valued at $811,000 after buying an additional 2,824 shares in the last quarter. Vanguard Group Inc. raised its position in Agile Therapeutics by 79.8% in the first quarter. Vanguard Group Inc. now owns 801,114 shares of the specialty pharmaceutical company’s stock valued at $2,568,000 after buying an additional 355,535 shares in the last quarter. Finally, Royce & Associates LP raised its position in Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after buying an additional 665,000 shares in the last quarter. 79.78% of the stock is currently owned by institutional investors and hedge funds.

Shares of Agile Therapeutics (NASDAQ:AGRX) traded down 1.04% during mid-day trading on Monday, reaching $3.80. The company had a trading volume of 128,442 shares. Agile Therapeutics has a one year low of $1.82 and a one year high of $8.15. The company’s market capitalization is $109.46 million. The company has a 50 day moving average price of $3.57 and a 200 day moving average price of $3.44.

TRADEMARK VIOLATION NOTICE: “-$0.28 Earnings Per Share Expected for Agile Therapeutics, Inc. (AGRX) This Quarter” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/06/26/0-28-earnings-per-share-expected-for-agile-therapeutics-inc-agrx-this-quarter.html.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.